We look forward to seeing builders innovating at the intersection of policy, biopharmaceutical manufacturing, financing, and clinical operations so we have viable means to bring these “miracle drugs” to market without bankrupting or breaking the system.
A trend is graded on whether the publisher keeps it, never as a hit or a miss (D6, D33).